New stock news | Binhe Biotechnology submits application to HKEX again

08:06 03/04/2026

According to the disclosure on April 2 by the Hong Kong Stock Exchange, Wuhan Biocan Technologies Co., Ltd. (referred to as: Biocan) has once again submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Huatai International, Zhongyin International, and BOCI Securities Limited acting as its joint sponsors.

According to the Hong Kong Stock Exchange's disclosure on April 2, Wuhan Binwill Biotechnology Co., Ltd. (referred to as Binwill Biotechnology) has once again submitted its listing application to the Hong Kong Stock Exchange main board, with Huatai International, CMB International, and BOC International as its joint sponsors. According to the prospectus, the company is a China-based oncolytic virus therapy biotechnology company, committed to the discovery, development, and commercialization of cancer immunotherapy. The company has independently developed the core product BS001 (OH2 injection) and two key products. As of the latest practicable date (March 27, 2026), the company's pipeline includes two clinical-stage candidate drugs (BS001 and BS006) and two preclinical-stage candidate drugs (BR003 and BS051).

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.

Energy crisis does not hinder the expansion ambition: Microsoft Corporation (MSFT.US) increases investment in Japan by $10 billion, joining forces with SoftBank and Sakura to build AI cloud infrastructure.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.